An Investigation of Early Life Stress and Depression

Mass General Brigham

Status and phase: Completed; Phase 1

Conditions: History of Childhood Sexual Abuse (CSA); Major Depressive Disorder (MDD)

Treatments: Drug: Placebo; Drug: Amisulpride

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT01701258

2012P002593

5R01MH095809 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to investigate brain pathways within adult females (with a history of CSA that occurred between the ages of 5-14) with and without a current diagnosis of major depressive disorder (MDD).

Hypotheses:

The CSA/MDD participants will be characterized by (1) reduced reward responsiveness and prefrontal cortex activity, but increased cortisol levels, (2) reduced dopamine activity, and (3) reduced dopamine transporter binding. The over-arching purpose of the study is to (1) identify individuals at risk for psychopathology and maladaptive behavior, (2) prevent re-victimization, and (3) develop more targeted therapeutic interventions.

Full description

This study will include four sessions:

Session 1 (SCID Session) The first session takes place at the Center for Depression, Anxiety, and Stress Research (CDASR) or Neuroimaging Center (both at McLean Hospital) and involves consenting, a clinical evaluation, a series of questionnaires, and a medical assessment.

Session 2 or 3 (fMRI Session) The third session takes place at the Neuroimaging Center. Using a double-blind design, participants will be administered either amisulpride (50 mg) or placebo. Participants will complete the Monetary Incentive Delay (MID) task during functional magnetic resonance imaging (fMRI) and the Probabilistic Stimulus Selection Task (PSST) afterwards.

Session 2 or 3 (PET Session) This session takes place at Massachusetts General Hospital. 9 mCi of [11C] altropane will be injected by a trained nuclear medicine technician and positron emission tomography (PET) scanning will begin. Prior to the PET scan, a blood serum pregnancy test will be administered for females.

Session 4 (ERP Session) The fourth session takes place at the CDASR and involves an electroencephalography (EEG) recording, the Probabilistic Reward Task (PRT), and collecting saliva samples to assess cortisol levels.

Enrollment: 153 patients

Sex: Female

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

General Inclusion Criteria:

• Females of all ethnic origins, age between 20 and 45; right-handed (Chapman & Chapman 1987);
• Absence of any psychotropic medications for at least 2 weeks (6 weeks for fluoxetine; 6 months for neuroleptics; 2 weeks for benzodiazepines; 2 weeks for any other antidepressants);

Inclusion Criteria for Childhood Sexual Abuse/MDD (CSA/MDD) Group:

• At least one incident of contact sexual abuse1 between the ages 5-14 years;
• Current DSM-IV diagnostic criteria for MDD (as diagnosed with the use of the SCID);

Inclusion Criteria for Childhood Sexual Abuse/Resilient (CSA/RES) Group:

• At least one incident of contact sexual abuse1 between the ages 5-14 years;
• Absence of past or current DSM diagnosis, including MDD or alcohol/substance abuse;

Inclusion Criteria for Non-traumatized, MDD (MDD) Group:

• No incidents of sexual, verbal, or physical abuse (ascertained using the Traumatic Antecedents Questionnaire);
• Current DSM-IV diagnostic criteria for MDD (as diagnosed with the use of SCID);

Non-traumatized, healthy controls (controls):

• No incidents of sexual, verbal, or physical abuse (ascertained using the Traumatic Antecedents Questionnaire);
• Absence of any medical, neurological, and psychiatric illness (including alcohol/substance abuse)

Exclusion Criteria:

• Participants with suicidal ideation where study participation is deemed unsafe by the study clinician;
• Pregnant women or women of childbearing potential who are not compliant with the requirements of a urine and blood pregnancy test.
• Failure to meet MRI or PET safety requirements.
• Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine (hypothyroidism), neurologic or hematologic disease;
• Past/current DSM diagnosis of: OCD, ADHD, schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder, mood congruent/incongruent psychotic features, substance dependence, substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse, which will lead to automatic exclusion);
• Simple phobia, social anxiety disorder and generalized anxiety disorders will be allowed only if secondary to MDD and only in the CSA/MDD and MDD groups (which will be matched for comorbidities);
• History of seizure disorder; renal insufficiency; history of adverse reactions to amisulpride;
• History of cocaine, stimulant, and other DA drug use [e.g., (meth)amphetamine), methylphenidate].

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

153 participants in 8 patient groups, including a placebo group

CSA/MDD-amisulpride

Active Comparator group

Description:

Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.

Treatment:

Drug: Amisulpride

CSA/MDD-placebo

Placebo Comparator group

Description:

Subjects experiencing a current episode of major depression (MDD) with a history of child sexual abuse (CSA) are randomized to receive a placebo during the fMRI session.

Treatment:

Drug: Placebo

CSA/RES-amisulpride

Active Comparator group

Description:

Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.

Treatment:

Drug: Amisulpride

CSA/RES-placebo

Placebo Comparator group

Description:

Subjects with a history of child sexual abuse (CSA) without a current or past diagnosis of major depressive disorder (RES) are randomized to receive a placebo during the fMRI session.

Treatment:

Drug: Placebo

MDD-amisulpride

Active Comparator group

Description:

Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.

Treatment:

Drug: Amisulpride

MDD-placebo

Placebo Comparator group

Description:

Subjects without a history of child sexual abuse that are currently experiencing a major depressive episode are randomized to receive a placebo during the fMRI session.

Treatment:

Drug: Placebo

Control-amisulpride

Active Comparator group

Description:

Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a single low-dose pharmacological challenge, 50mg amisulpride tablet during the fMRI session.

Treatment:

Drug: Amisulpride

Control-placebo

Placebo Comparator group

Description:

Subjects without a history of child sexual abuse and without a current or past diagnosis of major depressive episode are randomized to receive a placebo during the fMRI session.

Treatment:

Drug: Placebo